![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1467888
ºÎÀΰú °Ç°°ËÁø ½ÃÀå º¸°í¼ : À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)Women¢¥s Health Diagnostics Market Report by Type, Application, End User, and Region 2024-2032 |
ºÎÀΰú °Ç°°ËÁø ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 292¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC ±×·ìÀº 2032³â 526¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2024-2032³â°£ 6.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
ºÎÀΰú °ËÁøÀº ¿©¼º ȯÀÚÀÇ ´Ù¾çÇÑ »ý¹°ÇÐÀû, ½É¸®»çȸÀû »óŸ¦ Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼º ¹× Áú ¹®Á¦, ÀӽŠÇÕº´Áõ¿¡ ´ëóÇÏ°í °ñ´Ù°øÁõ, Æó°æ, À¯¹æ¾Ï, ÀڱðæºÎ¾Ï µî À§ÇùÀûÀÎ ÁúȯÀ» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. »ý°Ë, ÃÊÀ½ÆÄ °Ë»ç, ÈÇпä¹ý, ÀÚ±â°ø¸í¿µ»ó(MRI) µî ÀÏ·ÃÀÇ Ã·´Ü ÀÓ»ó °Ë»ç, µµ±¸ ¹× ±â¼úÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ÀϺΠÀÇ·á Áø´Ü¼¾ÅÍ´Â ¿©¼º¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â Èñ±ÍÁúȯ ¹× »óÅÂÀÇ Áø´Ü°ú °ü¸®¸¦ °ÈÇϱâ À§ÇØ ±¤¹üÀ§ÇÑ ÀÓ»ó °Ë»ç ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
¿©¼ºÀÇ Àü¹ÝÀûÀÎ À£ºù¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °Ç° ¹®Á¦ÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Á¶±â Áø´ÜÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ Àü ¼¼°èÀûÀ¸·Î ÇöÀå Áø·á(POC) ºÎÀΰú °ËÁø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ½ºÆ®·¹½º°¡ ¸¹Àº »ýȰ ¹æ½Ä°ú ¾ËÄÚ¿Ã ¹× ¾à¹° ¼·Ãë Áõ°¡·Î ÀÎÇÑ ºÒÀÓ·ü Áõ°¡´Â ÀӽŠÇÕº´Áõ¿¡ ´ëóÇÏ°í °Ç°ÇÑ »îÀ» º¸ÀåÇϱâ À§ÇØ ºÎÀΰú °ËÁøÀÇ Çʿ伺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æó°æ±â´Â ½ÉÇ÷°ü Áúȯ°ú ¿ä½Ç±Ý µî ƯÁ¤ ÁúȯÀÇ ¹ßº´ À§ÇèÀ» Áõ°¡½Ãų ¼ö Àֱ⠶§¹®¿¡ 50¼¼ ÀÌ»ó ¿©¼º Àα¸°¡ Å©°Ô Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ¿©·¯ ¿¬±¸¿¡ µû¸£¸é ¿©¼ºÀº È£¸£¸ó º¯È ½Ã ¿ì¿ïÁõÀ̳ª ºÒ¾ÈÁõ°ú °°Àº Á¤½Å ÁúȯÀ» °æÇèÇÒ °¡´É¼ºÀÌ ³ô´Ù´Â °á·ÐÀ» ³»¸®°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¿©¼ºÀÇ Á¤½Å °Ç°À» °³¼±Çϱâ À§ÇØ ¸¹Àº ±¹°¡ÀÇ º¸°Ç ±â°ü¿¡¼ ½ÃÇàÇϰí ÀÖ´Â ¿©·¯ ³ë·Â°ú ÇÔ²² Àü ¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
The global women's health diagnostics market size reached US$ 29.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.
Women's health diagnostics help diagnose various biological and psychosocial conditions of female patients. They assist in addressing sexual and vaginal issues and pregnancy complications and managing threatening diseases, such as osteoporosis, menopause, and certain cancers like breast and cervical. They rely on a series of advanced laboratory tests, tools, and procedures, which include biopsy, ultrasound, chemotherapy, and magnetic resonance imaging (MRI). Several healthcare diagnostics centers are currently offering an expansive range of laboratory testing solutions to enhance the diagnosis and management of rare diseases and conditions that affect women.
The rising prevalence of health issues that impact the overall well-being of women represents one of the major factors influencing the market positively. Moreover, the growing health consciousness, along with the increasing awareness about the benefits of early diagnosis, is catalyzing the demand for point-of-care (POC) women's health diagnostics across the globe. Apart from this, the rising rate of infertility on account of stressful lifestyles and the growing consumption of alcohol and drugs is driving the need for women's health diagnostics to address pregnancy complications and ensure a healthier life. Furthermore, as menopause can increase the risk of developing certain medical conditions, including cardiovascular diseases and urinary incontinence, a significant rise in the female population which is over 50 years is contributing to the market growth. Besides this, several research studies have concluded that women are more likely to experience psychiatric disorders, such as depression and anxiety, during hormonal changes. This, in confluence with several initiatives undertaken by health agencies of numerous countries to improve mental health of women, is propelling the market growth across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global women's health diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application, and end user.
Diagnostic Devices
Biopsy Device
Imaging and Monitoring Devices
Accessories and Consumables
Diagnostic Tests
Breast Cancer Testing
PAP Smear and HPV Test
Pregnancy Testing and Ovulation Testing
Others
Breast Cancer
Infectious Disease Testing
Osteoporosis Testing
Pregnancy and Fertility Testing
Sexually Transmitted Disease Testing
Others
Hospital and Diagnostics Centers
Home Care
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Cardinal Health Inc., Cook Group Incorporated, F. Hoffmann-La Roche AG, General Electric Company, Hologic Inc., Koninklijke Philips N.V., Perkinelmer Inc., Quest Diagnostics Inc., Siemens AG and Thermo Fisher Scientific Inc.